Bellerophon Therapeutics Inc., of Warren, N.J., named Fabian Tenenbaum chief financial officer and chief business officer.

Berg LLC, of Framingham, Mass., named Michael A. Kiebish chief precision medical officer.

Biorestorative Therapeutics Inc., of Melville, N.Y., added Robert B. Catell to its board.

Capricor Therapeutics Inc., of Los Angeles, appointed Leland J. Gershell chief financial officer.

Hemispherx Biopharma Inc., of Philadelphia, appointed William M. Mitchell board chairman, David R. Strayer chief scientific officer, and Adam Pascale chief financial officer in addition to his current role as chief accounting officer.

Melinta Therapeutics Inc., of New Haven, Conn., appointed John Temperato president and chief operating officer.

Neurovive Pharmaceutical AB, of Lund, Sweden, named Erik Kinnman CEO.

Mylan NV, of Canonsburg, Pa., named Anthony (Tony) Mauro chief commercial officer.

Pharnext SAS, of Paris, appointed Pierre Schwich chief financial officer and Niall Murphy chief scientific officer.

Pherecydes Pharma SA, of Romainville, France, named Guy-Charles Fanneau de La Horie CEO.

Vertice Pharma LLC, of London, appointed Scott Meyers chief operating officer.